#United States #Clinical Trials #Walnut Creek #Flourish Research #Diablo Clinical

Flourish Research Expands Its Network with Diablo Acquisition

Flourish Research, a prominent multi-site clinical trial organization, has officially acquired Diablo Clinical Research, marking a significant step in its growth strategy. This development allows Flourish to broaden its geographic presence and diversify its therapeutic capabilities, particularly in cardiovascular, metabolic, neuroscience, and infectious disease research areas.

About Diablo Clinical Research

Founded in 1995 and based in Walnut Creek, California, Diablo Clinical Research has established itself as a reputable facility specializing in various therapeutic areas. Over its 30-year history, Diablo has successfully conducted more than 1,000 trials, excelling mainly in endocrinology, cardiovascular, and metabolic studies. The facility's remarkable track record and expertise will undoubtedly foster Flourish's mission to deliver high-quality clinical research services.

Reinhold Schulz, Flourish's CEO, expressed his enthusiasm about this acquisition. He emphasized Diablo's reputation for high participant diversity and exceptional enrollment statistics. "Diablo expands our geographic footprint and enhances our therapeutic area coverage, allowing us to deliver top-notch service to our patients and reliable data for our clients," he stated.

The acquisition also merges the extensive experience of Diablo’s principal investigators and management team with Flourish’s operational strengths, boosting the capabilities both organizations can offer to sponsors and participants alike. Emily Galdes, Chief Operating Officer at Diablo, noted that both companies share a common mission: to advance clinical research for the benefit of patient health.

Strategic Importance of the Acquisition

This acquisition plays a crucial role in Flourish’s broader strategy of enhancing its research network, especially with its proximity to Silicon Valley—a hub for innovation in the medical device sector. According to Scott Niehaus, Managing Director at Genstar Capital, the firm that acquired Flourish, Diablo brings with it a prestigious clientele of sponsors and clinical research organizations (CROs). This strategic relationship will facilitate Flourish's entry into new device trials and partnerships with emerging biotech companies.

As clinical studies evolve and the demand for diverse and inclusive research escalates, this acquisition positions Flourish as a formidable player capable of meeting future challenges and opportunities in the clinical research landscape. The addition of Diablo’s capabilities is expected to reinforce Flourish's commitment to advancing clinical research efficiently and effectively.

The Way Forward

Flourish now operates a network of 26 sites with over 150 investigators, aiming to provide a reliable patient recruitment experience across all phases of clinical trials. It continues to be a leader in leveraging advanced technology and quality operations to ensure timely results for the biopharma sponsors it serves. The acquisition of Diablo will further solidify its position in the industry, enabling it to uphold its commitment to delivering quality research that can foster the development of life-enhancing therapies.

For further information about Flourish Research and its services, interested parties can visit Flourish Research's website. Meanwhile, the integration of Diablo's extensive operational knowledge and high standards will undoubtedly accelerate Flourish’s mission and expand its research horizons significantly.